GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » PuraPharm Corporation Ltd (HKSE:01498) » Definitions » 5-Year EBITDA Growth Rate

PuraPharm (HKSE:01498) 5-Year EBITDA Growth Rate

: 0.00% (As of Dec. 2023)
View and export this data going back to 2015. Start your Free Trial

PuraPharm's EBITDA per Share for the six months ended in Dec. 2023 was HK$-0.06.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 10 years, the highest 3-Year average EBITDA Per Share Growth Rate of PuraPharm was 37.00% per year. The lowest was -88.50% per year. And the median was 6.80% per year.


Competitive Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, PuraPharm's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PuraPharm 5-Year EBITDA Growth Rate Distribution

For the Drug Manufacturers industry and Healthcare sector, PuraPharm's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where PuraPharm's 5-Year EBITDA Growth Rate falls into.



PuraPharm 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.


PuraPharm  (HKSE:01498) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.


PuraPharm 5-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of PuraPharm's 5-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


PuraPharm (HKSE:01498) Business Description

Traded in Other Exchanges
N/A
Address
Wireless Centre, Phase One, Unit 201-207, 2nd Floor, Hong Kong Science Park, Tai Po, New Territories, Hong Kong, HKG
PuraPharm Corporation Ltd is a Hong Kong-based Chinese medicine Company. It is engaged in the research and development, production, marketing and sale of concentrated Chinese medicine granules (CCMG) products marketed under the brand Nong's. In addition, the organization is engaged in rendering Chinese medical diagnostic services. The operating segments of the group are China CCMG, Hong Kong CCMG, Chinese healthcare products, Plantation and Clinics. It generates maximum revenue from the China CCMG segment mainly engages in the production and sale of CCMG products in China. The group derives revenue from the customers located in Hong Kong, Mainland China and Other countries.

PuraPharm (HKSE:01498) Headlines

No Headlines